News
BARISTA trial demonstrates positive one-year results in treatment of illac artery lesions
2+ hour, 49+ min ago (259+ words) iVascular has announced the one-year results from the BARISTA trial, the first clinical trial with Restorer bare metal stent evaluating its safety and efficacy in the treatment of iliac artery lesions. The study provides evidence supporting the performance of Restorer…...
LUMIFOLLOW registry shows sustained three-year performance of Luminor in femoropopliteal disease
2+ hour, 31+ min ago (287+ words) LUMIFOLLOW registry shows sustained three-year performance of Luminor in femoropopliteal disease'Vascular News iVascular has revealed the three-year follow-up results from the LUMIFOLLOW registry, a large real-world study evaluating the safety and efficacy of the Luminor drug-coated balloon (DCB) in the…...
“Tissue identification”: How emerging technology is driving the next frontier in PE intervention
6+ day, 10+ hour ago (123+ words) Tissue identification: How emerging technology is driving the next frontier in PE intervention'Vascular News For the first time in its history, the American Venous Forum (AVF) put on a dedicated session focused on pulmonary embolism (PE) during its 2026 annual meeting…...
First ACC/AHA acute PE guidelines provide “roadmap” for management
1+ week, 3+ day ago (188+ words) A new severity-based classification system and strong endorsement for multidisciplinary pulmonary embolism response teams (PERTs) feature prominently in recently published multisociety guidelines on the evaluation and management of acute PE in adults. The American College of Cardiology (ACC)/American Heart…...
BD receives CE mark for Revello vascular covered stent
1+ week, 3+ day ago (225+ words) BD today announced it has obtained CE marking for the Revello vascular covered stent, which the company describes as a next-generation endovascular solution for the treatment of atherosclerotic lesions in the common and external iliac arteries. The Revello stent is…...
From bench to bedside: commercialising AI technologies in vascular care
3+ week, 3+ day ago (769+ words) From bench to bedside: commercialising AI technologies in vascular care'Vascular News Ben Li (Toronto, Canada) ponders the current state of artificial intelligence (AI) application in clinical practice, analysing the obstacles to scaled use. AI has reached a level of technical…...
LumiGuide outperforms standard FORS in complex aortic repair, SAVS audience hears
1+ mon, 3+ day ago (213+ words) In a study comparing Philips" Fiber Optic RealShape (FORS)-enabled guidewire with its enhanced successor LumiGuide, researchers found that the latter was associated with improved technical success and reduced procedure times. Huertas and colleagues" research stems from a need to…...
GE HealthCare’s Allia Moveo gains FDA and CE mark approvals
1+ mon, 1+ week ago (181+ words) GE HealthCare has announced that its Allia Moveo image-guidance platform has received US Food and Drug Administration (FDA) 510(k) clearance and CE mark. The latest Allia platform was first unveiled at the Radiological Society of North America's (RSNA) 2025 annual meeting (30 November4 December,…...
Post-approval study of EndoForce anastomotic connector commences with first cases
1+ mon, 2+ week ago (154+ words) Phraxis has announced the successful initiation of its post-approval study (PAS) for the EndoForce anastomotic connector, with the first procedure performed at Spartanburg Regional Healthcare System (Spartanburg, USA). This milestone marks a significant transition from regulatory achievement to the establishment…...
Revolutionising care: Drug-eluting stent platform designed to address edge restenosis poised to deliver next-generation solution in dialysis access circuit maintenance
1+ mon, 2+ week ago (253+ words) Revolutionising care: Drug-eluting stent platform designed to address edge restenosis poised to deliver next-generation solution in dialysis access circuit maintenance'Vascular News Effective, durable options to address faltering dialysis access circuits have remained elusive, leaving a significant unmet need in long-term…...